Podcast 22 Sep 2023Beyond Biotech podcast 64 – Precision immuno-oncology therapies Despite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response to existing therapies. In response to this critical challenge, Portage Biotech is on a mission to expand the number of patients who derive long-term […] September 22, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 15 Sep 2023Beyond Biotech podcast 63 – Fighting cancer with STRIs This week’s podcast is sponsored by Vetter. On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of cancer drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product candidates target the eIF4F complex and […] September 15, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 8 Sep 2023Beyond Biotech podcast 62 – cytokine-based drugs As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) […] September 8, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 1 Sep 2023Beyond Biotech podcast 61 – Blood Cancer Awareness Month On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed’s CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which […] September 1, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 25 Aug 2023Beyond Biotech podcast 60 – The cost of research On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […] August 25, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 18 Aug 2023Beyond Biotech podcast 59 – World Lung Cancer Day Since its inception in 2012, World Lung Cancer Day has been observed every year on August 1 in order to raise awareness of lung cancer issues and magnify the need for more lung cancer research funding. Around a quarter of a million people in the US alone will be diagnosed with some form of lung […] August 18, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 11 Aug 2023Beyond Biotech podcast 58 – Pepteins To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a […] August 11, 2023 Share WhatsApp Twitter Linkedin Email
Podcast 4 Aug 2023Beyond Biotech podcast 57: Group B Strep To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due […] August 4, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2023 Biogen acquiring Reata Pharmaceuticals for $7.3B Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […] July 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 Could a natural sweetener from hydrangeas treat Alzheimer’s disease? Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […] July 28, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2023 New CHAIN Biotech funding to aid CADD therapeutic platform CHAIN Biotechnology Limited has developed a therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. Its Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via stable, […] July 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email